Theragenics tests brachytherapy tech for macular degeneration
This article was originally published in Clinica
Executive Summary
Cancer brachytherapy products manufacturer Theragenics is to start a US clinical trial to assess whether its radiation treatment know-how can be used to treat patients with age-related macular degeneration (AMD), a leading cause of blindness.